The U.S. Food and Drug Administration has approved a nasal spray developed by Pfizer as a means of rapidly treating the painful symptoms associated with migraines.
The drug zabuzpret, also known as zavegepant, Approved Thursday For the treatment of acute migraine with or without aura in adults.expected to Released in July, Reuters reported.
“FDA approval of Zavzpret represents an important breakthrough for migraine sufferers who need pain relief and prefer alternatives to oral medications.
FDA’s go-ahead late test dataThis indicated that Zavzpret was more effective than placebo in 13 of the 17 test categories, including pain relief in 15 minutes and restoration of normal function in about 30 minutes. is included.
Of the 1,405 people who took part in the trial between October 2020 and August 2021, approximately 24% of those who took the drug reported being pain-free two hours after treatment, compared with 15% of those in the placebo group. said.
“When migraine attacks, it has a significant negative impact on daily life,” says Kathleen Mullin, M.D., associate medical director of the New England Institute of Neurology and Headache Research. “One of the most important attributes of any acute treatment option is how quickly it works.”
a Migraine is defined as a series According to the National Headache Foundation, at least 5 headache attacks lasting 4 to 72 hours. They can cause severe throbbing pain and a throbbing sensation in the head, accompanied by nausea, vomiting, or other symptoms such as sensitivity to light or sound.
